Ticker
ACIU

Price
2.57
Stock movement up
+0.05 (1.98%)
Company name
AC Immune Ltd
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
214.37M
Ent value
177.93M
Price/Sales
-
Price/Book
1.00
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-48.80%
3 year return
-31.28%
5 year return
-26.14%
10 year return
-
Last updated: 2022-12-05

DIVIDENDS

ACIU does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book1.00
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count83.41M
EPS (TTM)-0.90
FCF per share (TTM)-0.88

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-80.59M
Net income (TTM)-75.11M
EPS (TTM)-0.90
EPS (1y forward)-0.33

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash57.84M
Net receivables418.00K
Total current assets177.06M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets235.52M
Accounts payable501.00K
Short/Current long term debt2.77M
Total current liabilities11.91M
Total liabilities21.39M
Shareholder's equity214.13M
Net tangible assets163.72M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-71.49M
Capital expenditures (TTM)2.38M
Free cash flow (TTM)-73.88M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-35.08%
Return on Assets-31.89%
Return on Invested Capital-34.98%
Cash Return on Invested Capital-34.41%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.58
Daily high2.63
Daily low2.43
Daily Volume132K
All-time high19.30
1y analyst estimate11.41
Beta0.71
EPS (TTM)-0.90
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ACIUS&P500
Current price drop from All-time high-86.68%-14.82%
Highest price drop-87.82%-56.47%
Date of highest drop16 Jun 20229 Mar 2009
Avg drop from high-60.45%-11.46%
Avg time to new high520 days13 days
Max time to new high1556 days1805 days
COMPANY DETAILS
ACIU (AC Immune Ltd) company logo
Marketcap
214.37M
Marketcap category
Small-cap
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Employees
0
Investor relations
-
SEC filings
CEO
Andrea Pfeifer
Country
USA
City
Lausanne
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidateBased on...
November 30, 2022
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
November 25, 2022
Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on anti-phospho-Tau vaccines confirm safety, tolerability and...
November 23, 2022
LAUSANNE, Switzerland, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today ann...
November 8, 2022
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...
October 29, 2022
AC Immune (ACIU) delivered earnings and revenue surprises of 29.17% and 457.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
October 28, 2022
Announced initiation of dosing of anti-Abeta vaccine ACI-24.060 in the biomarker-based Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndromeReceived ...
October 28, 2022
Interim analysis expected around year-end 2022, informing Phase 2 startTrial progressing with regulatory clearances in the UK and also now in SpainPlanned submission of U.S. Investigational New Drug a...
October 4, 2022
AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD)AC Immune to receive a milestone payment from LMI for progress into late-stage product deve...
September 26, 2022
Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brainNew grant funding will pave the way for enha...
September 1, 2022
Next page